Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Nate Falk

Sports Medicine · FSU

View

Dr. Sarah Ro

Obesity Medicine · UNC Health Care

View

Dr. Christina Nguyen

Obesity Medicine · Knownwell

View

Dr. E. Robert Schwartz

Behavioral Medicine · University of Miami

View

Dr. Jennah Siwak

Obesity Medicine · Carle Foundation Hospital

View

Dr. Tema Fodje

General Family Medicine · U.S. Navy

View

Dr. Alfred Gitu

Primary Care · LMHS

View

Dr. Reid Blackwelder

General Family Medicine · ETSU

View

Dr. Bayo Curry-winchell

Primary Care · Clinicians Who Care

View

Dr. Kirsten Meisinger

Primary Care · CHA

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    MIDr. Moises Irizarry

    Dr. Moises Irizarry

    Family Medicine · Sports Medicine
    HCA Florida Mercy Hospital
    moisesi

    Research

    Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model

    2026

    Via CPT Pharmacometrics Syst Pharmacol

    Research

    Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress

    2026

    Via JAMA Netw Open

    Research

    Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effects

    2026

    Via NPJ Syst Biol Appl

    Research

    Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]

    2026

    Via J Prev Alzheimers Dis

    Research

    Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment

    2026

    Via Alzheimers Dement (N Y)

    Research

    Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ(+) and Aβ(-) dementia with Lewy bodies patients

    2026

    Via Alzheimers Res Ther

    Research

    Discordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake

    2026

    Via J Prev Alzheimers Dis

    Research

    Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease

    2026

    Via JAMA Neurol

    Research

    Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation

    2025

    Via J Prev Alzheimers Dis

    Research

    Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency

    2025

    Via Alzheimers Dement

    Research

    Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease

    2025

    Via J Neurol

    Research

    Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database

    2025

    Via Alzheimers Res Ther

    Research

    Feasibility of Identifying Acute Nontraumatic Intracerebral Hemorrhage Events Using Diagnostic Coding Among Veterans with Mild Cognitive Impairment or Alzheimer's Dementia

    2025

    Via Neurol Ther

    Research

    Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease

    2025

    Via Alzheimers Dement

    Research

    Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study

    2025

    Via Alzheimers Dement